Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis

Background: Triple-negative breast cancer (TNBC) and HER-2 negative metastatic breast cancer (HER-2 negative MBC) are intractable to various treatment schemes. Bevacizumab as a novel anti-VEGF drug, its safety for these two high-risk breast cancers remains controversial. Therefore, we conducted this...

Descripción completa

Detalles Bibliográficos
Autores principales: Xun, Xueqiong, Ai, Jun, Feng, Fuhui, Hong, Pan, Rai, Saroj, Liu, Ruikang, Zhang, Baowen, Zhou, Yeming, Hu, Huiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922898/
https://www.ncbi.nlm.nih.gov/pubmed/36794276
http://dx.doi.org/10.3389/fphar.2023.1108772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922898/
https://www.ncbi.nlm.nih.gov/pubmed/36794276
http://dx.doi.org/10.3389/fphar.2023.1108772

Ejemplares similares